Targeting the MGBA with -biotics in epilepsy: New insights from preclinical and clinical studies.
Neurobiol Dis
; 170: 105758, 2022 08.
Article
em En
| MEDLINE
| ID: mdl-35588991
ABSTRACT
BACKGROUND:
Data accumulation reveals that the bidirectional communication between the gut microbiota and the brain, called the microbiota-gut-brain axis (MGBA), can be modulated by different compounds including prebiotics, probiotics, symbiotic (a fair combination of both), and diet, thus exerting a beneficial impact on brain activity and behaviors. This review aims to give an overview of the possible beneficial effects of the supplementation of -biotics in epilepsy treatment.METHODS:
A search on PubMed and ClinicalTrials.gov databases using the terms "probiotics", OR "prebiotics", AND "gut microbiota", AND "epilepsy" was performed. The search covered the period of the last eleven years (2010-2021).CONCLUSIONS:
Nowadays, studies analyzing the clinical impact of gut microbiota-modulating intervention strategies on epilepsy are limited and heterogenous due either to the different experimental populations studied (i.e., genetic vs lesional mouse models) or the various primary outcomes measure evaluated. However, positive effects have invariably been noticed; particularly, there have been improvements in behavioral comorbidities and associated gastrointestinal (GI) symptoms. More studies will be needed in the next few years to strictly evaluate the feasibility to introduce these new therapeutic strategies in the clinical treatment of highly refractory epilepsies.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Probióticos
/
Epilepsia
/
Microbioma Gastrointestinal
/
Gastroenteropatias
Limite:
Animals
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article